Published finding — does the expert body still believe it?
Icosapent ethyl 4 g daily reduces the composite primary endpoint of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina by 25% (HR 0.75) compared to placebo in statin-treated patients with elevated triglycerides over a median 4.9-year follow-up.
TL;DR · AI-generated
Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than amongThose who received placebo.
Author-implied confidence
93%
Status
DRAFT
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
97% → 97% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
· openalex W2899669642 · s2 eaa96eb4
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.0220
Icosapent ethyl 4 g daily reduces the key secondary composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke by 26% (HR 0.74) compared to placebo in statin-treated patients with elevated triglycerides.
0.0461
Icosapent ethyl 4 g daily significantly reduces cardiovascular mortality (4.3% vs. 5.2%; HR 0.80) compared to placebo in statin-treated patients with elevated triglycerides.
0.1469
Icosapent ethyl 4 g daily is associated with a significantly higher rate of hospitalization for atrial fibrillation or flutter (3.1% vs. 2.1%) compared to placebo in statin-treated patients with elevated triglycerides.
0.1482
The cardiovascular benefit of icosapent ethyl observed in REDUCE-IT is attributable to mechanisms beyond triglyceride lowering alone, given the magnitude of risk reduction exceeds what triglyceride reduction alone would predict.
0.1608
Evolocumab added to statin therapy significantly reduced the composite primary endpoint of cardiovascular death, MI, stroke, unstable angina hospitalization, or coronary revascularization (HR 0.85; 95% CI 0.79–0.92) in ASCVD patients over a median 2.2-year follow-up.
0.1719
Evolocumab significantly reduced the key secondary composite endpoint of cardiovascular death, MI, or stroke (HR 0.80; 95% CI 0.73–0.88) compared with placebo in ASCVD patients receiving background statin therapy.